DelveInsight’s “Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market Forecast
Some of the key facts of the Celiac Disease Market Report:
-
The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In March 2024, First Wave BioPharma completed the acquisition of ImmunogenX through an all-stock deal, with the merged entity concentrating on advancing a gastrointestinal (GI) pipeline featuring several late-stage clinical assets, including latiglutenase. Additionally, the company revealed that two abstracts have been approved for showcasing at the 2024 Digestive Disease Week Conference (DDW 2024) held in Washington.
-
In October 2023, Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm specializing in orally administered, small molecule treatments for chronic inflammatory and autoimmune conditions, has unveiled findings from its phase 1b clinical trial of IMU-856. This trial explores the potential of IMU-856, an orally available small molecule modulator targeting SIRT6 (Sirtuin 6), in patients diagnosed with celiac disease. The data was presented in a moderated poster session at the United European Gastroenterology Week (UEGW) 2023, held from October 14-17 in Copenhagen.
-
In May 2023, Topas Therapeutics has initiated a Phase IIa clinical trial for TPM502 aimed at treating individuals with celiac disease, an autoimmune condition. This placebo-controlled, double-blind, randomized, multicenter study aims to evaluate the tolerability, safety, and pharmacodynamic effects of two TPM502 administrations across dose-escalating cohorts.
-
According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, accounting for about 1% of the population, are affected by celiac disease. Moreover, it is estimated that up to 83% of Americans with celiac disease remain undiagnosed or are misdiagnosed with other health conditions.
-
The average age of Celiac Disease diagnosis is estimated to range from 40 to 60 years old.
-
Key Celiac Disease Companies: First Wave BioPharma, Takeda, Sanofi (Provention Bio), Kanyos Bio, Topas Therapeutics GmbH, Massachusetts General Hospital, Alvine Pharmaceuticals, Immunogenics, LLC, Amgen, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
-
Key Celiac Disease Therapies: Latiglutenase (IMGX003), TAK-101; TAK-227; Zamaglutenase, PRV-015, KAN-101, TPM502, Ritlecitinib, ALV003, Latiglutenase, TAK-062, AMG 714, larazotide acetate, CCX282-B, BL-7010, and others
-
The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males
-
The Celiac Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.
Celiac Disease Overview
Celiac disease is an autoimmune disorder triggered by the consumption of gluten, a protein found in wheat, barley, and rye. When individuals with celiac disease ingest gluten, it causes an immune response that damages the small intestine’s lining, leading to various symptoms and potential complications.
Get a Free sample for the Celiac Disease Market Report:
https://www.delveinsight.com/report-store/celiac-disease-cd-market
Celiac Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Celiac Disease Epidemiology Segmentation:
The Celiac Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Celiac Disease
-
Prevalent Cases of Celiac Disease by severity
-
Gender-specific Prevalence of Celiac Disease
-
Diagnosed Cases of Episodic and Chronic Celiac Disease
Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Epidemiology Forecast
Celiac Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Celiac Disease Therapies and Key Companies
-
Latiglutenase (IMGX003): First Wave BioPharma
-
TAK-101; TAK-227; Zamaglutenase : Takeda
-
PRV-015 : Sanofi (Provention Bio)
-
KAN-101: Kanyos Bio
-
TPM502: Topas Therapeutics GmbH
-
Ritlecitinib: Massachusetts General Hospital
-
ALV003: Alvine Pharmaceuticals
-
Latiglutenase: Immunogenics, LLC
-
TAK-062: Takeda
-
AMG 714: Amgen
-
larazotide acetate: 9 Meters Biopharma, Inc.
-
CCX282-B: ChemoCentryx
-
BL-7010: BioLineRx, Ltd.
Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment Market
Celiac Disease Market Strengths
-
The pipeline activity of Celiac Disease is quite efficient with the presence of variable key players such as First Wave BioPharma, Sanofi, Takeda, etc., which are efficiently involved in developing milestone treatment options.
-
Latiglutenase has the potential to be a firstto-market treatment for celiac disease, a GIdisorder that impacts approximately three million people in the US and for which no approved pharmacologic treatment currently exists.
Celiac Disease Market Opportunities
-
Several organizations such as Celiac Disease Foundation, National Celiac Association (NCA), American Celiac Disease Alliance (Celiac Disease A), Coelic UK etc. are actively working to provide information and awareness of the disorder.
-
There is ongoing research into celiac disease, including potential treatments and therapies. Individuals with celiac disease can contribute to this research by participating in clinical trials or fundraising for research organizations.
Scope of the Celiac Disease Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Celiac Disease Companies: First Wave BioPharma, Takeda, Sanofi (Provention Bio), Kanyos Bio, Topas Therapeutics GmbH, Massachusetts General Hospital, Alvine Pharmaceuticals, Immunogenics, LLC, Amgen, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
-
Key Celiac Disease Therapies: Latiglutenase (IMGX003), TAK-101; TAK-227; Zamaglutenase, PRV-015, KAN-101, TPM502, Ritlecitinib, ALV003, Latiglutenase, TAK-062, AMG 714, larazotide acetate, CCX282-B, BL-7010, and others
-
Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
-
Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Celiac Disease Unmet Needs, KOL’s views, Analyst’s views, Celiac Disease Market Access and Reimbursement
To know more about Celiac Disease companies working in the treatment market, visit @ Celiac Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Celiac Disease Market Report Introduction
2. Executive Summary for Celiac Disease
3. SWOT analysis of Celiac Disease
4. Celiac Disease Patient Share (%) Overview at a Glance
5. Celiac Disease Market Overview at a Glance
6. Celiac Disease Disease Background and Overview
7. Celiac Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Celiac Disease
9. Celiac Disease Current Treatment and Medical Practices
10. Celiac Disease Unmet Needs
11. Celiac Disease Emerging Therapies
12. Celiac Disease Market Outlook
13. Country-Wise Celiac Disease Market Analysis (2020–2034)
14. Celiac Disease Market Access and Reimbursement of Therapies
15. Celiac Disease Market Drivers
16. Celiac Disease Market Barriers
17. Celiac Disease Appendix
18. Celiac Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/